HOME >> BIOLOGY >> NEWS
Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency

Researchers at The Rockefeller University, in collaboration with Genentech, Inc., have made a surprising discovery about the mechanism by which two currently used clinical antibodies fight tumors. The finding, reported in the April issue of Nature Medicine, has immediate implications for increasing the potency of an entire class of cancer drugs now on the market and for developing more effective drugs in the future.

"This should have a significant impact on immunotherapy for cancer," says senior author Jeffrey V. Ravetch, M.D., Ph.D., Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at Rockefeller. "There are more than 20 other antibodies now being developed that are in various stages of clinical trials, and this finding shows a way to make them much more effective."

The scientists discovered that two anti-tumor antibodies, Herceptin and Rituxan, operate by harnessing the immune system and directing it to kill tumor cells. The antibodies connect to the immune system by engaging receptor pairs on the surface of certain immune cells. One of these receptors acts as an "on" switch to initiate an immune response, while the other acts as an "off" switch to hold the immune system in check and prevent it from attacking the body.

As effective as Herceptin and Rituxan are, the researchers found that removing or disabling the "off" switch could make an antibody many times more potent than before. Ravetch says the technology to do so is within reach.

"It's startling to learn that these antibodies do not work the way everyone has assumed," Ravetch says. "Now that we recognize this in vivo mechanism, we should be able to manipulate it to great effectiveness."

Antibodies are natures own defense against foreign intruders. Antibody molecules comprise two main segments: a variable region, which is highly specific in order to recognize any foreign shapeor pathogenit may encounter; and the Fc do
'"/>

Contact: Jim Stallard
stallaj@rockvax.rockefeller.edu
212-327-8977
Rockefeller University
27-Mar-2000


Page: 1 2 3 4

Related biology news :

1. Rockefeller University scientists take on controversial vibration theory of smell
2. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
3. White House awards National Medal of Science to Rockefeller Universitys James Darnell
4. Lasker Award honors Rockefeller University biochemist for pioneering studies of gene activation
5. Rockefeller scientists identify natural proteins that push stem cells to produce hair, not skin
6. Rockefeller, Weill Cornell researchers find link between estrogen, brain structure changes
7. Rockefeller researchers provide the first functional evidence for mammalian pheromone receptors
8. Another transmembrane protein structure solved by Rockefeller scientists
9. Rockefeller researchers identify defense system in plants
10. Rockefeller University Centennial Symposium to explore biology of drug abuse and addiction
11. Rockefeller and Aaron Diamond researchers say resistance to HIV drugs may be higher than previously thought

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... , ... December 06, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
Breaking Biology Technology:
Cached News: